{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:20:25Z","timestamp":1786980025218,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hepatic lipid metabolism has been implicated in cancer development, with cholesterol dysregulation linked to tumor initiation and progression. We examined the association between low-density lipoprotein cholesterol (LDL) levels and prostate cancer (PCa) risk in the UK Biobank cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, community-based cohort study, conducted from March 2006 to December 2010, included 502,511 participants from the UK Biobank. Morbidity and mortality were analyzed in August 2023. Hazard ratios (HRs) for PCa related to hepatic blood value changes were calculated, adjusting for key variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We extracted 204,403 healthy men and 13,205 PCa patients, subdivided into 3751 with PCa at inclusion and 9454 who developed PCa during 14.1 years of follow-up. Elevated LDL\u2009\u2265\u20093.65 mmol\/L was associated with a reduced risk of PCa (HR\u2009=\u20090.83, 95% CI\u2009=\u20090.77\u20130.90,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). To exclude confounding from cardiovascular morbidity, we compared the prevalence of myocardial infarction, stroke, and peripheral arterial disease between LDL groups. The combined prevalence of myocardial infarction, stroke, or peripheral arterial disease was similar between low and high LDL (2.67% vs. 2.49%; OR\u2009=\u20090.93,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Fine\u2013Gray competing risk models further confirmed that high LDL remained inversely associated with PCa risk (sHR\u2009=\u20090.92, 95% CI\u2009=\u20090.88\u20130.96,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), indicating that the observed association is not explained by excess cardiovascular mortality or differential cardiovascular morbidity. A significant association was also found between paternal PCa and the risk of PCa (HR\u2009=\u20091.34, 95% CI\u2009=\u20091.16\u20131.54,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Elevated alanine aminotransferase (ALT\u2009\u2265\u200950 U\/L) was protective (HR\u2009=\u20090.69, 95% CI\u2009=\u20090.56\u20130.84,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), and matched cohort analyses confirmed a protective association with diabetes mellitus (HR\u2009=\u20090.78, 95% CI\u2009=\u20090.68\u20130.90,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated LDL was consistently associated with a reduced risk of PCa, independent of cardiovascular morbidity and competing mortality. ALT elevation and diabetes mellitus also showed protective associations, though less pronounced.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06313-4","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:37:01Z","timestamp":1772206621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elevated low-density lipoprotein cholesterol levels and prostate cancer risk: UK Biobank evidence"],"prefix":"10.1007","volume":"44","author":[{"given":"R.","family":"Alexa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Th\u00f6ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grundl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. H.","family":"Koop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Saar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"6313_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","volume":"4","author":"G Gandaglia","year":"2021","unstructured":"Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A et al (2021) Epidemiology and prevention of prostate cancer. Eur Urol Oncol 4:877\u2013892","journal-title":"Eur Urol Oncol"},{"key":"6313_CR2","doi-asserted-by":"crossref","unstructured":"Buxton AK, Abbasova S, Bevan CL, Leach DA (2022) Liver microenvironment response to prostate cancer metastasis and hormonal therapy. Cancers (Basel). 14 (24):6189","DOI":"10.3390\/cancers14246189"},{"key":"6313_CR3","doi-asserted-by":"crossref","unstructured":"Shiner A, Sperandio RC, Naimi M, Emmenegger U (2024) Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies. J Clin Med. 13(3):734","DOI":"10.3390\/jcm13030734"},{"key":"6313_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.euo.2018.06.010","volume":"2","author":"F Giunchi","year":"2019","unstructured":"Giunchi F, Fiorentino M, Loda M (2019) The metabolic landscape of prostate cancer. Eur Urol Oncol 2:28\u201336","journal-title":"Eur Urol Oncol"},{"key":"6313_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.euo.2019.07.005","volume":"4","author":"Y Wang","year":"2021","unstructured":"Wang Y, Jacobs EJ, Carter BD, Gapstur SM, Stevens VL (2021) Plasma metabolomic profiles and risk of advanced and fatal prostate cancer. Eur Urol Oncol 4:56\u201365","journal-title":"Eur Urol Oncol"},{"key":"6313_CR6","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/sj.bjc.6601206","volume":"89","author":"A Engeland","year":"2003","unstructured":"Engeland A, Tretli S, Bjorge T (2003) Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer 89:1237\u20131242","journal-title":"Br J Cancer"},{"key":"6313_CR7","first-page":"345","volume":"10","author":"C Rodriguez","year":"2001","unstructured":"Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ (2001) Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10:345\u2013353","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"6313_CR8","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.3390\/ijms15046184","volume":"15","author":"UJ Jung","year":"2014","unstructured":"Jung UJ, Choi MS (2014) Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 15:6184\u20136223","journal-title":"Int J Mol Sci"},{"key":"6313_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ypmed.2014.02.003","volume":"62","author":"HR Banack","year":"2014","unstructured":"Banack HR, Kaufman JS (2014) The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med 62:96\u2013102","journal-title":"Prev Med"},{"key":"6313_CR10","doi-asserted-by":"publisher","first-page":"29096","DOI":"10.1038\/s41598-024-80190-y","volume":"14","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Huang Z, Zhao Y, Wang Y, Niu Y (2024) Association between low density lipoprotein cholesterol levels and prostate cancer risk in non-hypertensive middle-aged and older American men. Sci Rep 14:29096","journal-title":"Sci Rep"},{"key":"6313_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40170-021-00278-1","volume":"10","author":"NL Raftopulos","year":"2022","unstructured":"Raftopulos NL, Washaya TC, Niederpr\u00fcm A, Egert A, Hakeem-Sanni MF, Varney B et al (2022) Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover. Cancer Metabolism 10:1","journal-title":"Cancer Metabolism"},{"key":"6313_CR12","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J et al (2015) UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12:e1001779","journal-title":"PLoS Med"},{"key":"6313_CR13","doi-asserted-by":"crossref","unstructured":"Harrell FE (2001) Regression modeling strategies. Springer Series in Statistics","DOI":"10.1007\/978-1-4757-3462-1"},{"key":"6313_CR14","doi-asserted-by":"crossref","unstructured":"Skara L, Hudek Turkovic A, Pezelj I, Vrtaric A, Sincic N, Kruslin B et al (2021) Prostate Cancer-Focus on Cholesterol. Cancers (Basel). 13(18):4696","DOI":"10.3390\/cancers13184696"},{"key":"6313_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.euf.2020.06.005","volume":"7","author":"H Goldberg","year":"2021","unstructured":"Goldberg H, Mohsin FK, Saskin R, Kulkarni GS, Berlin A, Kenk M et al (2021) The suggested unique association between the various statin subgroups and prostate cancer. Eur Urol Focus 7:537\u2013545","journal-title":"Eur Urol Focus"},{"key":"6313_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41391-020-0207-5","volume":"23","author":"A Kumar","year":"2020","unstructured":"Kumar A, Riviere P, Luterstein E, Nalawade V, Vitzthum L, Sarkar RR et al (2020) Associations among statins, preventive care, and prostate cancer mortality. Prostate Cancer Prostatic Dis 23:475\u2013485","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6313_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.eururo.2013.02.023","volume":"65","author":"NL Keating","year":"2014","unstructured":"Keating NL, Liu P-H, O\u2019Malley AJ, Freedland SJ, Smith MR (2014) Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 65:816\u2013824","journal-title":"Eur Urol"},{"key":"6313_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.eururo.2004.10.027","volume":"47","author":"A Tavani","year":"2005","unstructured":"Tavani A, Gallus S, Bertuzzi M, Dal Maso L, Zucchetto A, Negri E et al (2005) Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 47:313\u2013317","journal-title":"Eur Urol"},{"key":"6313_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/pcan.2012.40","volume":"16","author":"D Bansal","year":"2013","unstructured":"Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P (2013) Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis 16:151\u2013158","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6313_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41416-020-0910-y","volume":"123","author":"X Feng","year":"2020","unstructured":"Feng X, Song M, Preston MA, Ma W, Hu Y, Pernar CH et al (2020) The association of diabetes with risk of prostate cancer defined by clinical and molecular features. Br J Cancer 123:657\u2013665","journal-title":"Br J Cancer"},{"key":"6313_CR21","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1158\/0008-5472.CAN-15-1551","volume":"76","author":"RC Travis","year":"2016","unstructured":"Travis RC, Appleby PN, Martin RM, Holly JMP, Albanes D, Black A et al (2016) A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res 76:2288\u20132300","journal-title":"Cancer Res"},{"key":"6313_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/gerona\/glq082","volume":"65","author":"DG Le Couteur","year":"2010","unstructured":"Le Couteur DG, Blyth FM, Creasey HM, Handelsman DJ, Naganathan V, Sambrook PN et al (2010) The association of alanine transaminase with aging, frailty, and mortality. J Gerontol Biol Sci Med Sci 65:712\u2013717","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"6313_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ejim.2014.10.019","volume":"25","author":"E Ramaty","year":"2014","unstructured":"Ramaty E, Maor E, Peltz-Sinvani N, Brom A, Grinfeld A, Kivity S et al (2014) Low ALT blood levels predict long-term all-cause mortality among adults. A historical prospective cohort study. Eur J Intern Med 25:919\u2013921","journal-title":"Eur J Intern Med"},{"key":"6313_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10147-019-01578-9","volume":"25","author":"K Mori","year":"2020","unstructured":"Mori K, Janisch F, Parizi MK, Mostafaei H, Lysenko I, Enikeev DV et al (2020) Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. Int J Clin Oncol 25:247\u2013257","journal-title":"Int J Clin Oncol"},{"key":"6313_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41391-022-00554-1","volume":"25","author":"EL Craig","year":"2022","unstructured":"Craig EL, Stopsack KH, Evergren E, Penn LZ, Freedland SJ, Hamilton RJ et al (2022) Statins and prostate cancer-hype or hope? The epidemiological perspective. Prostate Cancer Prostatic Dis 25:641\u2013649","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06313-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06313-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06313-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:02:20Z","timestamp":1781636540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06313-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6313"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06313-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8025728\/v1","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The UK Biobank study was approved by the North West Multicenter Research Ethics Committee (project 71300) and was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"210"}}